Results 51 to 60 of about 7,551 (201)

TCRγδ(+)CD4(-)CD8(-) T cells suppress the CD8(+) T-cell response to hepatitis B virus peptides, and are associated with viral control in chronic hepatitis B. [PDF]

PLoS ONE, 2014
The immune mechanisms underlying failure to achieve hepatitis B e antigen (HBeAg) seroconversion associated with viral control in chronic hepatitis B (CHB) remain unclear.
Qintao Lai, Shiwu Ma, Jun Ge, Zuxiong Huang, Xuan Huang, Xiaotao Jiang, Yongyin Li, Mingxia Zhang, Xiaoyong Zhang, Jian Sun, William G H Abbott, Jinlin Hou   +11 more
doaj   +1 more source

A one-year trial of lamivudine for chronic hepatitis B [PDF]

, 1998
Background and Methods: In preliminary trials, lamivudine, an oral nucleoside analogue, has shown promise for the treatment of chronic hepatitis B. We conducted a one-year double-blind trial of lamivudine in 358 Chinese patients with chronic hepatitis B.
Barber, J, Chang, TT, Chien, RN, Dent, JC, Gray, DF, Guan, R, Lai, CL, Leung, NWY, Ng, KY, Stephenson, SL, Tai, DI, Wu, PC   +11 more
core   +1 more source

Incidence and Characteristics of HBV Reactivation‐Related Events Following HBsAg Seroclearance: Long‐Term Follow‐up of a Population‐Based Cohort in Japan

Hepatology Research, EarlyView.
In a population‐based cohort in Japan, HBV reactivation‐related events were observed after HBsAg seroclearance, including one virologically confirmed hepatic flare occurring spontaneously without chemotherapy or immunosuppression. These findings indicate that HBsAg seroclearance does not always represent complete viral eradication, supporting the need ...
Kazumi Yamasaki, Satoshi Shirahama, Takahiro Yasaka, Shota Yamaguchi, Masashi Mizokami, Junko Tanaka, Hiroaki Okamoto, Hiroshi Yatsuhashi   +7 more
wiley   +1 more source

HBsAg seroclearance in the chronic hepatitis B patients whom naïve and nucleos(t)ide analogue-treated: a long-term follow-up study

The Turkish Journal of Gastroenterology, 2019
This study was conducted in Trabzon Karadeniz Technical University Faculty of Medicine, Department of Infectious Diseases. Spontaneous HBsAg seroclearance is infrequent in adult HBV infection.
Iftihar Koksal, Bengü Pakyurek, Gurdal Yilmaz   +2 more
doaj   +1 more source

Toward a Functional Cure for Chronic Hepatitis B: Current Landscape and Future Directions in Japan

Hepatology Research, EarlyView.
Hepatitis B is a viral liver infection that can become chronic, increasing the risk of developing liver cancer and liver failure. Because current treatments rarely cure these problems, researchers are now focusing on a functional cure in which the virus becomes undetectable in blood and stays that way, even after the treatment ends.
Yutaka Handa, Ethan Yichen Lee, Yasuhito Tanaka   +2 more
wiley   +1 more source

Mutations in pre-core and basal-core promoter regions of hepatitis B virus in chronic HBV patients from Golestan, Iran [PDF]

, 2014
Objective(s): It has been reported that the mutation of the pre-core (PC) and basal-core promoter (BCP) may play an important role in the development of HBV-related hepatocellular carcinoma (HCC).
Bazouri, M., Ghaemi, A., Javid, N., Moradi, A., Tabarraei, A., Zhand, S.   +5 more
core   +2 more sources

Then and now: the progress in hepatitis B treatment over the past 20 years. [PDF]

, 2014
The ultimate goals of treating chronic hepatitis B (CHB) is prevention of hepatocellular carcinoma (HCC) and hepatic decompensation. Since the advent of effective antiviral drugs that appeared during the past two decades, considerable advances have been ...
Halegoua-De Marzio, Dina, Hann, Hie-Won
core   +2 more sources

Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Virus Infection in the High‐Replicative Low‐Inflammatory Phase: A 48‐Week Randomized Controlled Trial

Journal of Medical Virology, Volume 98, Issue 5, May 2026.
ABSTRACT Antiviral treatment for chronic HBV infection in the “high‐replicative low‐inflammatory” phase has not been widely recommended. This study aimed to evaluate the safety and efficacy of antiviral therapy in this patient population and analyze peripheral immunological characteristics in relation to treatment response.
Qiumin Luo, Ruixuan Xu, Yeqiong Zhang, Wenxiong Xu, Xiangyong Li, Jing Lai, Jianguo Li, Xingrong Zheng, Hong Deng, Lubiao Chen, Xiang Zhu, Chan Xie, Liang Peng   +12 more
wiley   +1 more source

Overcoming Immunotolerance in Chronic Hepatitis B: Efficacy of Granulocyte‐Macrophage Colony‐Stimulating Factor–Based Immunotherapy in Achieving Hepatitis B Surface Antigen Seroclearance

MedComm, Volume 7, Issue 4, April 2026.
Chronic hepatitis B patient (CHB) presents a challenge due to immune tolerance toward HBV surface antigen (HBsAg). This study aimed to achieve a functional cure by disrupting HBV tolerance through immunotherapy. CHB received standard NA therapy, or NA combined with IFN‐α, while a third group received the THRIL‐GM‐Vac regimen.
Shuang Geng, Feifei Yang, Hongyu Jia, Gan Zhao, Weidong Zhao, Jie Yu, Haoxiang Zhu, Huan Cai, Lishan Yang, Shuren Zhang, Fang Yu, Xiang Jin, Shijie Zhang, Xianzheng Wang, Yida Yang, Jiming Zhang, Bin Wang   +16 more
wiley   +1 more source

Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 8, Page 1089-1098, April 2026.
Serum HBV RNA levels at viral suppression predict HCC development in nucleos(t)ide analogue‐treated patients with chronic hepatitis B, outperforming Hepatitis B core‐related antigen alone. ABSTRACT Background Despite achieving undetectable hepatitis B virus (HBV) DNA levels with nucleos(t)ide analogue (NA) therapy, patients with chronic hepatitis B ...
Takashi Kumada, Hidenori Toyoda, Satoshi Yasuda, Yuichi Koshiyama, Takanori Ito, Tomoyuki Akita, Junko Tanaka   +6 more
wiley   +1 more source